

Hepatitis C Treatment Updates and CCO Support for Management

PA is not required for most members and CCOs can still help support successful treatment

Despite the removal of PA on most HepC drugs, prescribing rates have not improved since COVID-19 significantly reduced new start treatment rates. The CDC recommends screening all adults aged 18 and older in nearly all settings.

Additionally, based on a recent claims review, CareOregon has found that 1 in 10 members do not refill their HepC medication after the first month. While this likely means 90% are having successful treatment, this means dozens of members are not getting the life-changing benefit of achieving a sustained viral response (SVR).

Preferred Hepatitis C Drugs Do Not Require PA for Treatment Naive:

- Mavyret- Most situations clinically only require 8 weeks. Up to 16 weeks is available without PA.
- Generic Epclusa- Most situations clinically only require 12 weeks, but up to 24 can be received without PA.
- The claims system will look for any evidence of a previous course of therapy with a protease inhibitor.
- Note: In some cases (such as reinfection or limited first treatment course), it may be clinically appropriate for a second course to be approached as treatment naïve. However, prior authorization will be required if claims see a past treatment.

Non-preferred drugs:

- Vosevi- This will remain on formulary, but with a prior authorization. It is reserved for retreatment scenarios as specified in the PA criteria.
- Pediatric formulations- while supported in some clinical situations they are no longer preferred to reflect the fact that prior authorization will be required in all instances.
- Competing brands including Harvoni and brand Epclusa will require prior authorization. Their use will need to meet existing PA criteria as well as a medical reason to avoid using preferred regimens identified in the table of the Hepatitis C PA criteria.

Case Management

- Case management includes assessing drug interactions, addressing potential barriers to adherence, & providing support for other comorbidities that may impact successful treatment.
- **Case management can be optionally requested for drugs without PA.**
- Case management is required for treatments that require prior authorization
 - » Patients can elect to opt-out of case management.
- For additional details on case management and how to request it, **please see our website www.careoregon.org/providers/pharmacy-resources for a HepC Case Management Request Form.**
- Clinics can:
 - » Attest to perform all case management directly; or
 - » Request partial assistance from the CCO; or
 - » Request full assistance with case management from the CCO.